Information  X 
Enter a valid email address

Angle PLC Ord 10P (AGL)

Date Time Source Announcement
04 Jun 2018 7:00 am
RNS
ENCOURAGING PROGRESS IN ANG-002 FDA CLINICAL STUDY
14 May 2018 7:00 am
RNS
Leading cancer surgeon appointed
03 May 2018 7:00 am
RNS
Angle & QIAGEN Poster
19 Apr 2018 7:00 am
RNS
Parsortix in multiple presentations at AACR
  7:00 am
RNS
Breakthrough Research with Parsortix
05 Apr 2018 7:00 am
RNS
First patient enrolled in FDA study
26 Mar 2018 4:35 pm
RNS
Price Monitoring Extension
  7:00 am
RNS
Research Update
06 Feb 2018 7:00 am
RNS
ANGLE plc: RESEARCH GRANT FROM ABBOTT
31 Jan 2018 7:00 am
RNS
Interim Results
16 Jan 2018 7:00 am
RNS
WEBINAR:USING PARSORTIX TO TEST DRUGS ON LIVE CTCS
10 Jan 2018 10:16 am
RNS
Notice of Results
08 Jan 2018 7:00 am
RNS
ANGLE plc:Prostate cancer ARV7 treatment biomarker
27 Dec 2017 11:49 am
RNS
Holding(s) in Company
12 Dec 2017 7:00 am
RNS
Transfer of Lock-in Shares
08 Dec 2017 7:00 am
RNS
PARSORTIX POTENTIAL IN METASTATIC BREAST CANCER
28 Nov 2017 7:00 am
RNS
Parsortix enables CTC molecular characterisation
23 Nov 2017 7:00 am
RNS
PHILIPS COLLABORATION IN BREAST AND RECTAL CANCER
17 Nov 2017 4:06 pm
RNS
Holding(s) in Company
16 Nov 2017 8:23 am
RNS
Total Voting Rights and Covington Subscription
06 Nov 2017 7:00 am
RNS
Holding(s) in Company
  7:00 am
RNS
Holding(s) in Company
  7:00 am
RNS
Holding(s) in Company
  7:00 am
RNS
Holding(s) in Company
02 Nov 2017 10:04 am
RNS
Holding(s) in Company
01 Nov 2017 8:12 am
RNS
ANGLE: Completion of Fundraising and Acquisition
31 Oct 2017 2:18 pm
RNS
Result of AGM
30 Oct 2017 10:31 am
RNS
Result of General Meeting
26 Oct 2017 8:10 am
RNS
Total Voting Rights
23 Oct 2017 7:00 am
RNS
Parsortix harvests cancer cells from bone marrow
20 Oct 2017 3:05 pm
RNS
Notice of AGM
17 Oct 2017 7:00 am
RNS
ANGLE: 7th Peer Reviewed Publication On Parsortix
12 Oct 2017 7:00 am
RNS
Proposed further subscription for �2.8 million
09 Oct 2017 7:02 am
RNS
CTCs harvested with Parsortix grown in laboratory
  7:01 am
RNS
Potential new analytical protocol using Parsortix
  7:00 am
RNS
Parsortix Showcased at CTC Conference
05 Oct 2017 11:46 am
RNS
Results of Fundraising
  7:00 am
RNS
Acquisition and Fundraising
13 Sep 2017 5:36 pm
RNS
Holding(s) in Company
  7:00 am
RNS
Exclusive worldwide option over megakaryocyte IP
11 Sep 2017 7:00 am
RNS
Co-Marketing Partnership with QIAGEN
05 Sep 2017 7:00 am
RNS
Change of Adviser
04 Sep 2017 7:00 am
RNS
New Research with Parsortix
27 Jul 2017 7:00 am
RNS
Preliminary Results
20 Jul 2017 1:00 pm
RNS
Preclinical Study Presented At Tumor Boston Summit
06 Jul 2017 10:05 am
RNS
Notice of Results
04 Jul 2017 7:00 am
RNS
Successful Headline Data in Ovarian Cancer Studies
15 Jun 2017 7:00 am
RNS
Parsortix breakthrough in prostate cancer
05 Jun 2017 7:00 am
RNS
Success with Parsortix in Colorectal Cancer
03 May 2017 7:00 am
RNS
Business Update
04 Apr 2017 7:00 am
RNS
Holding(s) in Company
03 Apr 2017 7:00 am
RNS
Parsortix enables analysis in head and neck cancer
30 Mar 2017 7:00 am
RNS
Prostate Cancer Update
13 Feb 2017 7:00 am
RNS
Selected for European Cancer ID Programme
26 Jan 2017 7:01 am
RNS
Interim Evaluation of Ovarian Cancer Study
  7:00 am
RNS
Interim Results
04 Jan 2017 7:00 am
RNS
Notice of Results
28 Nov 2016 7:00 am
RNS
ISSUE OF SHARE OPTIONS
24 Nov 2016 2:48 pm
RNS
Result of GM
04 Nov 2016 7:00 am
RNS
Barts Research Supports Potential Use of Parsortix
 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t